By Digifin Pty Ltd · About this coverage
Key Points
- Sabra footprint expanded from two facilities to 23 communities across five operators
- 808 contracted memory care licences across the 23 communities
- Management estimates 1.2 million potential licences and A$100 million addressable market, not guidance
- Silverado paid pilot covers 203 licences across two sites, first site live end of September 2026
- No contract value or revenue disclosed for the new licences

About PainChek (ASX:PCK)
PainChek Limited is an ASX-listed health technology company headquartered in Sydney. It develops a smartphone-based pain assessment application for people who cannot reliably report their pain, used in aged care and other care settings.
PainChek (ASX:PCK) reported that its US master services agreement with Sabra Health Care REIT has turned into contracts at more communities, as its new leadership focuses US sales on assisted living and memory care.
PainChek has added 21 Sabra sites, taking its footprint from the two Traditions memory care facilities announced on 4 June 2026 to 23 communities across five operators (AgeWell, HDG, Phoenix Senior Living, The Claiborne and Traditions Senior Living), with a total of 808 contracted memory care licences. Those operators have 192 communities across their wider portfolios. Management estimates the US assisted living and memory care segment at approximately 1.2 million potential licences, with an estimated total addressable market value of A$100 million, which the company states is an estimate rather than contracted demand or revenue guidance. A separate paid pilot with Silverado covers 203 licences across two sites, with the first site going live at the end of September 2026. Silverado operates 31 sites, which the company estimates as a 2,500 licence opportunity. Skilled nursing, hospitals and home care remain part of the US strategy, to be sequenced according to integration readiness, workflows and reimbursement and regulatory requirements.
The release gives no contract value, pricing or revenue for the 808 licences. Further expansion depends on operator engagement and additional contracts, and any Silverado expansion depends on the pilot's evaluation.
Source: PainChek Limited (ASX:PCK), 13 October 2026. Summary content supplied by Digifin Pty Ltd.
News summary only, not financial advice. It does not consider your objectives, financial situation or needs.
